^McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. McLaughlin, P.; Grillo-López, A. J.; Link, B. K.; Levy, R.; Czuczman, M. S.; Williams, M. E.; Heyman, M. R.; Bence-Bruckler, I.; White, C. A.; Cabanillas, F.; Jain, V.; Ho, A. D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B. K. (1998 Aug). . „Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program”. J Clin Oncol. 16 (8): 2825—33. PMID9704735. doi:10.1200/JCO.1998.16.8.2825.Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. Edwards, Jonathan C.W.; Szczepański, Leszek; Szechiński, Jacek; Filipowicz-Sosnowska, Anna; Emery, Paul; Close, David R.; Stevens, Randall M.; Shaw, Tim (2004 Jun 17). . „Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis”. N Engl J Med. 350 (25): 2572—81. PMID15201414. doi:10.1056/NEJMoa032534.Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Brændstrup, Peter; Bjerrum, Ole W.; Nielsen, Ove J.; Jensen, Bjarne A.; Clausen, Nielsaage T.; Hansen, Per Boye; Andersen, Ivan; Schmidt, Kai; Andersen, Torben M.; Peterslund, Niels A.; Birgens, Henrik S.; Plesner, Torben; Pedersen, Bjarne B.; Hasselbalch, Hans C. (2005 Apr). . „Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura”. Am J Hematol. 78 (4): 275—80. PMID15795920. doi:10.1002/ajh.20276.Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. . . 108 (6): 1975—8. 2006 Sep 15. PMID16705086.Проверите вредност парамет(а)ра за датум: |date= (помоћ); Недостаје или је празан параметар |title= (помоћ). Epub 2006 May 16.
^Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med. . . 348 (26): 2690—1. 2003 Jun 26. PMID12826649.Проверите вредност парамет(а)ра за датум: |date= (помоћ); Недостаје или је празан параметар |title= (помоћ); discussion 2690-1.
